Cited by 142Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor: A Meta-analysis

Lee, June-Koo, Hahn, Seokyung, Kim, Dong-Wan, Suh, Koung Jin, Keam, Bhumsuk, Kim, Tae Min, Lee, Se-Hoon, Heo, Dae Seog·2014·JAMA

DOI 10.1001/jama.2014.3314

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Current guidelines recommend both epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic chemotherapy drugs as standard treatment options for patients with wild-type (WT) EGFR who were previously treated for non-small cell lung cancer (NSCLC). However, it is not clear that EGFR TKIs are as efficacious as chemotherapy in patients with WT EGFR. OBJECTIVE: To determine the association between first-generation EGFR TKI vs chemotherapy and survival in advanced NSCLC patients with WT EGFR. DATA SOURCES: PubMed, EMBASE, Cochrane database, and meeting abstracts of the American Society of Clinical Oncology and European Society of Medical Oncology through December 2013. STUDY SELECTION: Eligible studies were randomized controlled trials comparing EGFR TKI with conventional chemotherapy in patients with advanced NSCLC. Out of 1947 retrieved articles, 11 trials incorporating 1605 patients with WT EGFR were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers extracted trial characteristics and outcomes. The risk of bias was evaluated using the Cochrane tool. All measures were pooled using random-effects models and 95% CIs were calculated. MAIN OUTCOMES AND MEASURES: The primary outcome was progression-free survival (PFS), measured as hazard ratios (HRs). The secondary outcomes were objective response rate and overall survival, expressed as relative risks and HRs, respectively. RESULTS: Among patients with WT EGFR tumors, chemotherapy was associated with improvement of PFS, compared with TKI (HR for TKI, 1.41; 95% CI, 1.10-1.81). No statistically significant subgroup difference was identified in terms of line of treatment (first-line vs second- or later-line), experimental drug, dominant ethnicity, or EGFR mutation analysis method. Trials using more sensitive platforms than direct sequencing were associated with a significant PFS benefit with chemotherapy (HR for TKI, 1.84; 95% CI, 1.35-2.52). The association of chemotherapy with improvement in PFS was also significant in second- or later-line trials (HR, 1.34; 95% CI, 1.09-1.65). The objective response rate was higher with chemotherapy (92/549, 16.8%, vs 39/540, 7.2%, for TKI; relative risk for TKI, 1.11; 95% CI, 1.02-1.21); however, no statistically significant difference was observed with respect to overall survival (HR for TKI, 1.08; 95% CI, 0.96-1.22). CONCLUSIONS AND RELEVANCE: Among patients with advanced NSCLC harboring WT EGFR, conventional chemotherapy, compared with first-generation EGFR TKI, was associated with improvement in PFS but not overall survival.

Integrity signals

Registry

Crossref · 10.1001/jama.2014.3314

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Show all 47 references

Sorted by citations

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716
Overview of current systemic management of EGFR-mutant NSCLC
Hsu, W.-H., Yang, J. C., Mok, T. S. K., & Loong, H. H.-F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx702 · Cited by 394
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 234
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis
Yang, Z., Hackshaw, A. K., Feng, Q., Fu, X., Zhang, Y., Mao, C., & Tang, J.-L. (2017) · International Journal of Cancer · doi:10.1002/ijc.30691 · Cited by 213
Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR -Mutant Advanced Non–Small Cell Lung Cancer
Hong, S., Gao, F., Fu, S., Wang, Y., Fang, W., Huang, Y., & Zhang, L. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0049 · Cited by 183
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
Arrieta, O. G., Barrón, F., Ramírez-Tirado, L. A., Zatarain-Barrón, Z. L., Cardona, A. F., Díaz-García, D. A., Ramos, M. Y., Mota-Vega, B., Carmona, A., Álvarez, M. P. P., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0409 · Cited by 154
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
Ramalingam, S. S., Janne, P. A., Mok, T. S. K., O'Byrne, K. J., Boyer, M. J., von Pawel, J., Płużański, A., Shtivelband, M. I., Docampo, L. I., Bennouna, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70452-8 · Cited by 143
Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer
Créquit, P., Trinquart, L., Yavchitz, A., & Ravaud, P. (2016) · BMC Medicine · doi:10.1186/s12916-016-0555-0 · Cited by 126
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
Yang, C., Lin, M., Chang, Y., Wu, C., & Yang, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.033 · Cited by 122
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Koulouris, A., Tsagkaris, C., Corriero, A. C., Metro, G., & Mountzios, G. (2022) · Cancers · doi:10.3390/cancers14143337 · Cited by 102
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
Canale, M., Andrikou, K., Priano, I., Cravero, P., Pasini, L., Urbini, M., Delmonte, A., Crinò, L., Bronte, G., & Ulivi, P. (2022) · Cancers · doi:10.3390/cancers14051143 · Cited by 97
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma
Takada, K., Okamoto, T., Toyokawa, G., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Takamori, S., Katsura, M., Shoji, F., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.006 · Cited by 72
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial
Zhou, Q. H., Cheng, Y., Yang, J., Zhao, M., Zhang, L., Zhang, X.-C., Chen, Z., Yan, H., Song, Y., Chen, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu463 · Cited by 66
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib
Younes, M., Wu, Z., Dupouy, S., Mansuet‐Lupo, A., Mourra, N., Takahashi, T., Fléjou, J. F., Trédaniel, J., Régnard, J. F., Damotte, D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1633 · Cited by 65
MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2
Gao, F., Wu, H., Wang, R., Guo, Y., Zhang, Z., Wang, T., Zhang, G., Liu, C., & Liu, J. (2019) · Bioengineered · doi:10.1080/21655979.2019.1586056 · Cited by 64
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Lee, Y., Lee, K. H., Lee, G. K., Lee, S.-H., Lim, K. Y., Joo, J., Go, Y., Lee, J. S., & Han, J. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.546 · Cited by 63
Self-citation
What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
Bernabé, R., Hickson, N., Wallace, A. J., & Blackhall, F. H. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.022 · Cited by 62
SBRT for oligoprogressive oncogene addicted NSCLC
Basler, L., Kroeze, S. G. C., & Gückenberger, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.007 · Cited by 59
Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer
Lau, S. C. M., Batra, U., Mok, T. S. K., & Loong, H. H.-F. (2019) · Drugs · doi:10.1007/s40265-019-01115-y · Cited by 57
Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the “Hispanic paradox”
Arrieta, O. G., Ramírez-Tirado, L.-A., Báez-Saldaña, R., Peña‐Curiel, O., Soca‐Chafre, G., & Macedo-Pérez, E. O. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.010 · Cited by 55
Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines
Rodríguez, R. B., & Fuentes, J. M. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0200-6 · Cited by 56
Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer
Evrard, S., Clermont, E., Rouquette, I., Murray, S. J., Dintner, S., Nam‐Apostolopoulos, Y., Bellosillo, B., Varela, M., Nadal, E., Wiedorn, K. H., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.010 · Cited by 49
Targeting EGFR in lung cancer: Lessons learned and future perspectives
Steuer, C. E., & Ramalingam, S. S. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.004 · Cited by 46
Treatment of advanced non-small-cell lung cancer
Prabhash, K., Vora, A. D., Limaye, S. A., Sahoo, T. P., Batra, U., Patil, S., Patil, V., Noronha, V., Bhosale, B., Raut, N. V., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_61_21 · Cited by 46
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers
CHOUAID, C., Luciani, L., Lay, K. L., Dô, P., Bennouna, J., Pérol, M., Moro‐Sibilot, D., Vergnenégre, A., & de Pouvourville, G. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.013 · Cited by 43
Addressing the unmet need in lung cancer: The potential of immuno-oncology
Scagliotti, G. V., Bironzo, P., & Vansteenkiste, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.001 · Cited by 41
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
Carmichael, J. A., Mak, D. W.-S., & O’Brien, M. (2018) · Cancers · doi:10.3390/cancers10070236 · Cited by 42
Past, Present, and Future of Anticancer Nanomedicine
Kim, K., & Khang, D. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s254774 · Cited by 39
A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer
Fan, Y., Huang, Z., Fang, L., Miao, L., Gong, L., Yu, H., Yang, H., Lei, T., & Mao, W. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2760-5 · Cited by 40
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
Ji, J., Aredo, J. V., Piper‐Vallillo, A. J., Huppert, L. A., Rotow, J. K., Husain, H., Stewart, S., Cobb, R. G., Wakelee, H. A., Blakely, C. M., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100459 · Cited by 38
Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer
Jeong, M.-S., Lee, K., Choi, Y.-J., Kim, Y.-G., Hwang, H.-H., Lee, S.-Y., Jung, S.-E., Park, S.-A., Lee, J. H., Joo, Y.-J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168405 · Cited by 38
Self-citation
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination
Jeon, Y. K., Kim, C. K., Koh, J., Chung, D. H., & Ha, G. (2016) · Oncotarget · doi:10.18632/oncotarget.9619 · Cited by 36
EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review
Tsiambas, E., Lefas, A. Y., Georgiannos, S. N., Ragos, V., Fotiades, P. P., Grapsa, D., Σταματελόπουλος, Α., Kavantzas, N., Patsouris, E., & Syrigos, K. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.005 · Cited by 38
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer
Tagliamento, M., Genova, C., Rijavec, E., Rossi, G., Biello, F., Bello, M. G. D., Alama, A., Coco, S., Boccardo, S., & Grossi, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1540591 · Cited by 33
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors
Meniawy, T. M., Lake, R., McDonnell, A. M., Millward, M., & Nowak, A. K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.12.006 · Cited by 31
CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma
Shang, X., Li, J., Wang, H., Li, Z., Lin, J., Chen, D., & Wang, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106864 · Cited by 31
2‐Heteroaryl‐[1,2,4]triazolo[1,5‐c]quinazoline‐5(6 H)‐thiones and Their S‐Substituted Derivatives: Synthesis, Spectroscopic Data, and Biological Activity
Билый, А. К., Antypenko, L., В.В., І., Kamyshnyi, O., Поліщук, Н. М., & Коваленко, С. І. (2015) · ChemPlusChem · doi:10.1002/cplu.201500051 · Cited by 32
Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats
Shan, X., Zhang, Y., Chen, H., Dong, L., Wu, B., Xu, T., Hu, J., Liu, Z., Wang, W., Wu, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15790 · Cited by 31
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
Ulivi, P., Delmonte, A., Chiadini, E., Calistri, D., Papi, M., Mariotti, M., Verlicchi, A., Ragazzini, A., Capelli, L., Gamboni, A., et al. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010747 · Cited by 30
CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway
Yang, F., Zhang, S., Meng, Q., Zhou, F., Pan, B., Liu, F., & Yu, Y. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102001 · Cited by 27
Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non–Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy
Lim, Y. J., Chang, J. H., Kim, H.-J., Keam, B., Kim, T. M., Kim, D., Paeng, J. C., Kang, K. W., Chung, J.-K., Jeon, Y. K., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.013 · Cited by 29
Self-citation
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
Ou, S.-H., & Soo, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s52787 · Cited by 28
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung
Goss, G. D., & Spaans, J. N. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0209 · Cited by 28
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
Bluthgen, M. V., & Besse, B. (2015) · European Respiratory Review · doi:10.1183/16000617.00002115 · Cited by 25
CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor
Liu, B., Song, S., Setroikromo, R., Chen, S., Hu, W., Chen, D., van der Wekken, A. J., Melgert, B. N., Timens, W., van den Berg, A., et al. (2019) · Cancers · doi:10.3390/cancers11040455 · Cited by 22
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
Peters, S., Stahel, R. A., Dafni, U. G., Ponce-Aix, S., Massutí, B., Gautschi, O. P., Coate, L. E., Martín, A. L., van Heemst, R. C., Berghmans, T., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.017 · Cited by 22
Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma
Tian, Y., Zhao, J., Ren, P., Wang, B., Zhao, C., Shi, C., Wei, B., Ma, J., & Guo, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201682 · Cited by 22
An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China
Wei, W., Mao, N., Ning, S., Li, J., Liu, H., Xie, T., Zhong, J., Feng, Y., Wei, C., & Zhang, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168795 · Cited by 22
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation
Huang, S., Long, Y., Gao, Y., Lin, W., Wang, L., Jiang, J., Yuan, X., Chen, Y., Zhang, P., & Chu, Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00565-9 · Cited by 23
Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials
Vale, C. L., Burdett, S., Fisher, D. J., Navani, N., Parmar, M., Copas, A. J., & Tierney, J. F. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.11.007 · Cited by 22
Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations
Barnfield, P. C., & Ellis, P. M. (2016) · Drugs · doi:10.1007/s40265-016-0628-6 · Cited by 20
Treatment on advanced NSCLC: Platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials
Zhou, J., Tian, X., Wang, X., Tian, J., Wang, Y., Wang, F., Zhang, Y., & Ma, H. (2015) · Medical Oncology · doi:10.1007/s12032-014-0471-0 · Cited by 19
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Kim, J., Park, S., Ku, B. M., & Ahn, M. (2025) · Cancer · doi:10.1002/cncr.35778 · Cited by 20
EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma
Toki, M. I., Carvajal‐Hausdorf, D., Altan, M., McLaughlin, J. F., Henick, B. S., Schalper, K. A., Syrigos, K. N., & Rimm, D. L. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.025 · Cited by 17
Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China
You, R., Liu, J., Wu, D. B.-C., Qian, X., Lyu, B., Zhang, Y., & Luo, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s219722 · Cited by 17
Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC
Peng, W., Yao, C., Pan, Q., Zhang, Z., Ye, J., Shen, B., Zhou, G., & Fang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120278 · Cited by 18
PLCε signaling in cancer
Zhang, R., Du, W., Zhang, Y., Zheng, J., & Pei, D. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1999-x · Cited by 17
Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum
Zhu, J., Qi, Y., Wu, J., Shi, M., Feng, J., & Chen, L. (2016) · Oncology Letters · doi:10.3892/ol.2016.5295 · Cited by 17
Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC
Almotlak, A. A., Farooqui, M., & Siegfried, J. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.195 · Cited by 16
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
Zhou, F., & Zhou, C. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0036-4 · Cited by 17
The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer
Ma, H., Tian, X., Zeng, X., Zhang, Y., Wang, Y., Wang, F., & Zhou, J. (2016) · Medicine · doi:10.1097/md.0000000000002495 · Cited by 15
Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis
Ying, M., Zhu, X., Chen, K., Sha, Z., & Chen, L. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1910-9 · Cited by 15
C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFRT790M mutant
Song, A., Zhang, J., Yang, G., Wang, C., Meng, Q., Tang, Z., Peng, J., Liu, K., Li, Y., & Ma, X. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.032 · Cited by 15
Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.
Han, X., Luo, R., Wang, L., Zhang, L., Wang, T., Zhao, Y., Xiao, S., Qiao, N., Xu, C., Ding, L., et al. (2020) · PubMed Central · Cited by 15
Immunohistochemistry for EGFR Mutation Detection in Non–Small-Cell Lung Cancer
Hitij, N. T., Kern, I., Sadikov, A., Knez, L., Stanič, K., Zwitter, M., & Čufer, T. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.021 · Cited by 14
A Transcriptome Sequencing Study on Genome-Wide Gene Expression Differences of Lung Cancer Cells Modulated by Fucoidan
Zhao, Y., Li, X., Zhang, H., Yan, M., Jia, M., & Zhou, Q. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.844924 · Cited by 14
Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Compassion of MCF7 and MDA-MB-231 Cancer Cell LinesPreprint
San-Millán, I., Martinez, J. L., Pickard, S. L., Yu, H., Hirsch, F. R., Rivard, C. J., & Brooks, G. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.23.533060 · Cited by 14
Nanomedicines: intervention in inflammatory pathways of cancer
Anwar, F., Naqvi, S., Shams, S., Sheikh, R. A., Al-Abbasi, F. A., Asseri, A. H., Baig, M. R., & Kumar, V. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01217-w · Cited by 13
Pharmacological management of relapsed/refractory NSCLC with chemical drugs
Karachaliou, N., Sosa, A. E., Barrón, F., Cao, M. G., Santarpía, M., & Rosell, R. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285284 · Cited by 13
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
Köhler, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00009 · Cited by 13
Antitumor effects of erlotinib in combination with berberine in A431 cells
Cuan, X., Yang, X., Zhu, W., Zhao, Y., Luo, R., Huang, Y., Wang, X., & Sheng, J. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00661-2 · Cited by 13
The Prognostic Significance of pSTAT1 and CD163 Expressions in Surgically Resected Stage 1 Pulmonary Squamous Cell Carcinomas
Lin, M., Yang, C., Kuo, S., Wu, C., Chang, Y., & Yang, P. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5244-x · Cited by 12
Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma
Cao, Y., Xu, H., Liao, M., Qu, Y., Xu, L., Zhu, D., Wang, B., & Tian, S. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1197-8 · Cited by 13
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
Tibaldi, C., Lunghi, A., & Baldini, E. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i4.320 · Cited by 11
Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy
Fidler, M. J., Frankenberger, C. A., Seto, R., Lobato, G. C., Fhied, C. L., Sayidine, S., Basu, S., Pool, M. D., Karmali, R., Batus, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17510 · Cited by 10
Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis
Tsiambas, E., MASTRONIKOLIS, N. S., Lefas, A. Y., Georgiannos, S. N., Ragos, V., Fotiades, P. P., Tsoukalas, N., Kavantzas, N., Karameris, A., Peschos, D., et al. (2017) · In Vivo · doi:10.21873/invivo.11106 · Cited by 11
Evaluating the tumor biology of lung adenocarcinoma: A multimodal analysis
Kim, K. H., Ryu, S.-Y., Lee, H. Y., Choi, J. Y., Kwon, O. J., Kim, H. K., & Shim, Y. M. (2019) · Medicine · doi:10.1097/md.0000000000016313 · Cited by 11
PLCε regulates metabolism and metastasis signaling via HIF‐1α/MEK/ERK pathway in prostate cancer
Fan, Y., Ou, L., Fan, J., Luo, L., Wang, X., Niu, L., Wu, X., & Luo, C. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29698 · Cited by 11
DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer
Kim, T. Y., Ji, E. S., Lee, J. Y., Kim, J. Y., Yoo, J. S., Szász, A. M., Döme, B., Marko‐Varga, G., & Kwon, H. J. (2020) · Cancers · doi:10.3390/cancers12092613 · Cited by 11
Self-citation
EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del / L858R mutations
Xia, L., Wang, H., He, X., Lan, B., Liu, J., & Yang, Z. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13554 · Cited by 12
In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy
Guisier, F., Bohn, P., Patout, M., Piton, N., Farah, I., Véra, P., Thiberville, L., & Salaün, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180576 · Cited by 11
Mechanism of targeting the mTOR pathway to regulate ferroptosis in NSCLC with different EGFR mutations
Wu, C., Zhong, R., Wei, T., Jin, Y., He, C., Li, H., & Cheng, Y. (2024) · Oncology Letters · doi:10.3892/ol.2024.14431 · Cited by 13
Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis
Hu, Y., Liu, S., Wang, L., Liu, Y., Zhang, D., & Zhao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202822 · Cited by 10
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis
Kang, E. J., Min, K. H., Hur, G. Y., Lee, S. Y., Shim, J. J., Kang, K. H., Oh, S. C., Seo, J. H., & Kim, J. S. (2015) · Chemotherapy · doi:10.1159/000440941 · Cited by 10
Self-citation
Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis
Sholl, L. M. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.019 · Cited by 10
The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update
Matikas, A., Georgoulias, V., & Kotsakis, A. P. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1240620 · Cited by 10
Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary Teams
Murgu, S. D., Rabito, R., Lasko, G., Jackson, C., Mino-Kenudson, M. A., Ettinger, D. S., Ramalingam, S. S., & Edell, E. S. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.11.032 · Cited by 10
Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Wei, L., Lao, Y., Fu, T., Xie, Z., Wang, Y., Yang, T., Huang, L., Liu, J., Shu, M., Tian, T., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.04.007 · Cited by 9
Association of study design features and treatment effects in trials of chronic medical conditions: a meta-epidemiological study
Wang, Z., Alahdab, F., Farah, M. H., Seisa, M. O., Firwana, M., Rajjoub, R., Saadi, S. M., Jawaid, T., Nayfeh, T., & Murad, M. H. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2021-111667 · Cited by 9
Efficacy of second‑line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non‑small cell lung cancer without epidermal growth factor receptor mutations
Lee, S. Y., Kang, E. J., Lee, S., Kim, H. K., Min, K. H., Hur, G. Y., Shim, J. J., Kang, K. H., Oh, S. H., Seo, J., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7350 · Cited by 8
Self-citation
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer
Zimmermann, S., & Peters, S. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9560-6 · Cited by 8
A New Predictive Scoring System Based on Clinical Data and Computed Tomography Features for Diagnosing EGFR-mutated Lung Adenocarcinoma
Cao, Y., & Xu, H. (2018) · Current Oncology · doi:10.3747/co.25.3805 · Cited by 8
A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer
Minemura, H., Yokouchi, H., Azuma, K., Hirai, K.-I., Sekine, S., Oshima, K., Kanazawa, K., Tanino, Y., Inokoshi, Y., Ishii, T., et al. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1214-9 · Cited by 7
VeriStrat validated in patients with non-small-cell lung cancer
Butts, C. A. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70203-7 · Cited by 7
Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis
Li, A., Huang, X., Song, Y., Chen, X., Sun, J., Xu, H., & Wang, Z. (2015) · Growth Factors · doi:10.3109/08977194.2015.1010643 · Cited by 6
Retraction Note to: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials
Liu, J., Sheng, Z., Zhang, Y., & Li, G. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0468-z · Cited by 6
Retracted
Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung
Ghosh, M., Mukhopadhyay, M., Das, C., Chatterjee, S., & Ghosh, B. N. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_99_20 · Cited by 5
RETRACTED ARTICLE: The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials
Liu, J., Sheng, Z., Zhang, Y., & Li, G. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0376-7 · Cited by 5
Retracted

Authors: Lee, J.-K., Hahn, S., Kim, D.-W., Suh, K. J., Keam, B., Kim, T. M., Lee, S.-H., & Heo, D. S.
Affiliations: Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
Seoul National University (KR)
ORCID: Hahn, Seokyung
Kim, Dong-Wan
Suh, Koung Jin
Keam, Bhumsuk
Kim, Tae Min
Lee, Se-Hoon
Heo, Dae Seog
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2014-04-09
Volume: 311
Issue: 14
Pages: 1430
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2014.3314
OpenAlex: W2158043872
Cited by: 141
References: 47
Citations by year: 2025: 5 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 8 · 2020: 7 · 2019: 10 · 2018: 8 · 2017: 24 · 2016: 27 · 2015: 25 · 2014: 12
FWCI: 23.55
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: EGFR tyrosine kinase inhibitors, non-small cell lung cancer, EGFR wild-type, cytotoxic chemotherapy, progression-free survival, overall survival, objective response rate, EGFR mutation testing, EGFR mutation status, first-line therapy, second-line therapy, randomized controlled trials meta-analysis, risk of bias assessment, subgroup analysis
MeSH terms: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Protein-Tyrosine Kinases, Randomized Controlled Trials as Topic, Disease-Free Survival, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor: A Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks